Clostridium septicum (C. septicum)

Clostridium septicum is a Gram-positive, anaerobic, spore-forming bacterium that is a significant human pathogen, primarily known for causing spontaneous gas gangrene (myonecrosis) [1.1.1, 1.1.5]. Unlike other clostridia, it is highly aerotolerant and can infect healthy tissues without prior trauma, often disseminating hematogenously from the gastrointestinal tract [1.1.4, 1.3.1]. This infection is strongly associated with underlying malignancies, particularly colorectal cancer and hematological diseases, which provide a portal of entry [1.1.4, 1.3.2]. The primary virulence factor is the alpha-toxin, a pore-forming cytolysin that causes extensive tissue necrosis and hemolysis [1.2.1, 1.2.4]. The toxin is secreted as an inactive protoxin that is activated by host proteases, subsequently oligomerizing to form pores in cell membranes, leading to osmotic lysis [1.2.4, 1.2.5]. Clinical presentation often includes rapid onset of pain, swelling, and systemic toxicity, frequently leading to death within 24 to 48 hours if not treated promptly [1.2.1, 1.3.1]. Therapeutic management requires a combination of aggressive surgical debridement and intensive antibiotic therapy, typically involving penicillin and clindamycin to inhibit bacterial growth and toxin production [1.1.1, 1.1.3].

Other names

Vibrion septiqueBacillus septicus

Antibiotics target bacterial cell wall synthesis (penicillins), protein synthesis (clindamycin, tetracycline), or DNA synthesis (metronidazole) to inhibit growth or kill the pathogen.